JP2022527373A5 - - Google Patents
Info
- Publication number
- JP2022527373A5 JP2022527373A5 JP2021559435A JP2021559435A JP2022527373A5 JP 2022527373 A5 JP2022527373 A5 JP 2022527373A5 JP 2021559435 A JP2021559435 A JP 2021559435A JP 2021559435 A JP2021559435 A JP 2021559435A JP 2022527373 A5 JP2022527373 A5 JP 2022527373A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence described
- lcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024002528A JP7688175B2 (ja) | 2019-04-10 | 2024-01-11 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
| JP2025085725A JP2025113406A (ja) | 2019-04-10 | 2025-05-22 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832218P | 2019-04-10 | 2019-04-10 | |
| US62/832,218 | 2019-04-10 | ||
| PCT/US2020/027554 WO2020210551A1 (en) | 2019-04-10 | 2020-04-09 | Human antibodies that bind ret and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002528A Division JP7688175B2 (ja) | 2019-04-10 | 2024-01-11 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527373A JP2022527373A (ja) | 2022-06-01 |
| JP2022527373A5 true JP2022527373A5 (https=) | 2023-01-10 |
| JP7511576B2 JP7511576B2 (ja) | 2024-07-05 |
Family
ID=70554175
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559435A Active JP7511576B2 (ja) | 2019-04-10 | 2020-04-09 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
| JP2024002528A Active JP7688175B2 (ja) | 2019-04-10 | 2024-01-11 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
| JP2025085725A Pending JP2025113406A (ja) | 2019-04-10 | 2025-05-22 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002528A Active JP7688175B2 (ja) | 2019-04-10 | 2024-01-11 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
| JP2025085725A Pending JP2025113406A (ja) | 2019-04-10 | 2025-05-22 | Ｒｅｔを結合するヒト抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220185900A1 (https=) |
| EP (1) | EP3953390A1 (https=) |
| JP (3) | JP7511576B2 (https=) |
| KR (1) | KR20210150509A (https=) |
| CN (1) | CN113993898B (https=) |
| AU (1) | AU2020270966B2 (https=) |
| CA (1) | CA3134258A1 (https=) |
| IL (1) | IL287067A (https=) |
| MA (1) | MA55615A (https=) |
| MX (1) | MX2021012335A (https=) |
| WO (1) | WO2020210551A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024503508A (ja) | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | 免疫調節性抗体－薬物コンジュゲート |
| BR112023015561A2 (pt) | 2021-02-03 | 2023-11-14 | Univ Minnesota | Compostos imunoestimuiladores e conjugados |
| US20250154236A1 (en) * | 2022-01-31 | 2025-05-15 | Glaxosmithkline Intellectual Property (No. 3) Limited | Prevention and treatment of headaches |
| EP4518905A1 (en) | 2022-05-06 | 2025-03-12 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| JP2025525904A (ja) | 2022-08-03 | 2025-08-07 | シージェン インコーポレイテッド | 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| TW202541841A (zh) * | 2023-12-20 | 2025-11-01 | 美商黛安瑟斯醫療運營公司 | 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US20090202562A1 (en) * | 2005-06-17 | 2009-08-13 | Biogen Idec Ma Inc. | Anti-gfralpha3 antibodies |
| EP1941909A4 (en) * | 2005-10-24 | 2012-05-23 | Takeda Pharmaceutical | PREVENTIVE MEASURES / REMEDIES FOR CANCER |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| PT2387583T (pt) | 2009-01-14 | 2018-12-24 | Ablynx Nv | Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos |
| PT2438087T (pt) | 2009-06-05 | 2017-08-04 | Ablynx Nv | Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| JO3462B1 (ar) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| GB201512215D0 (en) * | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| EP3356415B1 (en) * | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| KR101859576B1 (ko) * | 2016-06-30 | 2018-05-18 | 가톨릭대학교 산학협력단 | Kif5b-ret 융합 단백질을 특이적으로 검출하는 항체 및 이의 용도 |
| AU2018336785B2 (en) * | 2017-09-20 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden |
-
2020
- 2020-04-09 MX MX2021012335A patent/MX2021012335A/es unknown
- 2020-04-09 KR KR1020217036432A patent/KR20210150509A/ko active Pending
- 2020-04-09 AU AU2020270966A patent/AU2020270966B2/en active Active
- 2020-04-09 WO PCT/US2020/027554 patent/WO2020210551A1/en not_active Ceased
- 2020-04-09 CA CA3134258A patent/CA3134258A1/en active Pending
- 2020-04-09 US US17/602,562 patent/US20220185900A1/en active Pending
- 2020-04-09 CN CN202080042521.7A patent/CN113993898B/zh active Active
- 2020-04-09 EP EP20724257.9A patent/EP3953390A1/en active Pending
- 2020-04-09 MA MA055615A patent/MA55615A/fr unknown
- 2020-04-09 JP JP2021559435A patent/JP7511576B2/ja active Active
-
2021
- 2021-10-07 IL IL287067A patent/IL287067A/en unknown
-
2024
- 2024-01-11 JP JP2024002528A patent/JP7688175B2/ja active Active
-
2025
- 2025-05-22 JP JP2025085725A patent/JP2025113406A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527373A5 (https=) | ||
| Zhang et al. | The role of interleukin-17 in inflammation-related cancers | |
| Zhong et al. | A novel IL6 antibody sensitizes multiple tumor types to chemotherapy including trastuzumab-resistant tumors | |
| EP3894013A1 (en) | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent | |
| JP2024028805A (ja) | がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療 | |
| TW201904995A (zh) | IL-1β 結合抗體之用途 | |
| JP2015514113A (ja) | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 | |
| CN114761013A (zh) | 治疗骨髓纤维化和相关病症的方法 | |
| Schinzari et al. | Targeted therapy in advanced gastric carcinoma: the future is beginning | |
| US20230088070A1 (en) | Use of il-1beta binding antibodies | |
| US20230101029A1 (en) | Methods of using il-33 protein in treating cancers | |
| US20250092127A1 (en) | IL-4/IL-13 Pathway Inhibitors for Enhanced Efficacy in Treating Cancer | |
| JP2024038034A (ja) | 膀胱癌の抗ｐｄ－ｌ１抗体治療 | |
| Duong et al. | T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review | |
| JP2020510673A (ja) | がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法 | |
| JP2019527697A5 (https=) | ||
| JP7341130B2 (ja) | 癌を治療するための組成物および治療方法 | |
| US20160324962A1 (en) | Compositions and methods for treating sarcoma | |
| RU2021129250A (ru) | Человеческие антитела, связывающие ret, и способы их применения | |
| Wu et al. | Next‐Generation HER‐2 Tumor‐Targeted Delivery of the STING Agonist Immune‐Stimulating Antibody Conjugate (ISAC) Improves Anticancer Efficacy and Induces Immunological Memory | |
| Al-Batran et al. | Recent advances and future trends in the targeted therapy of metastatic gastric cancer | |
| WO2016003789A1 (en) | Combination therapy | |
| JP2023511277A (ja) | Ｃｃｒ５陽性の転移性のがんの処置のためのｃｃｒ５結合剤 | |
| US20220089740A1 (en) | Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer | |
| Garrido et al. | The anti-tumor activity of the 7A7 antibody, specific to murine EGFR, is independent of target expression levels in immunocompetent mice |